# Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC

> **NCT07480694** · — · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 400 (estimated)

## Conditions studied

- Treatment Efficacy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07480694
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-12
- **Final completion:** 2028-02
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07480694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07480694, "Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07480694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*